Project duration:

Number of students for this project:

4-6 weeks



Globally, fungal diseases kill 1.5-2 million people annually. The mortality rates for invasive infections caused by the three most common human fungal pathogens; Candidia albicans (20-40%), Aspergillus fumigatus (50-90%) and Cryptococcus neoformans (20-70%) are staggeringly high. The impact of these infections is felt particularly in the developing world, for example ~ 500,000 people die annually in sub-Saharan Africa because of infection by C. neoformans. Throughout the world, the impact of invasive fungal diseases continues to increase as the cohort of immunocompromise individuals grows. Toxicity and access are the major limitations impeding effective antifungal treatment. For example, Amphotericin B, the most board-spectrum and potent antifungal on the market, is highly nephrotoxic and availability is limited in the developing world. Consequently, there appears to be an unmet clinical need for novel antifungals. The project aims to assess the clinical need for novel antifungal through market research and a market validations process, providing information on opportunities that exists within the fungal market and the characteristic of a successful antifungal drug.


Suitable academic background:

Suitable for students with a background in Biotechnology (essential), Microbiology, Molecular Biology, and Biochemistry.


Skills obtained in the project:

Applicants will gain knowledge surrounding the antifungal market. Applicants will gain experience in collecting, analyzing and interpreting market information. 


Primary Supervisor:


Assoc Prof James Fraser


Further info: